Mary Abuzzahab
Pediatric Endocrinology · Saint Paul, MNNPI 1174515274
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 47.3% of the total. 2025 is the largest year on record at $36,548, more than ten times the $2,072 reported in 2020. Among pediatric endocrinology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $1009.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$29K
- Ascendis Pharma Endocrinology Inc$13K
- Rhythm Pharmaceuticals, Inc.$8K
- Endo Pharmaceuticals Inc.$7K
- Novo Nordisk$2K
- Eton Pharmaceuticals, Inc.$2K
- plus $1K from 2 others
Across 2,813 payments — averaging $417.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rhythm Pharmaceuticals, Inc.$434K
- Novo Nordisk AS$276K
- Soleno Therapeutics, Inc.$240K
- Ascendis Pharma Endocrinology Inc$195K
- Novo Nordisk Health Care AG$17K
- Pfizer$10K
- plus $3K from 1 others
What the payments were for
- Consulting fees$35,87458%
- Speaking & faculty fees$14,99124%
- Travel & lodging$9,10415%
- Food & beverage$1,4272%
- Education$1880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 22 | $29,147 |
| Ascendis Pharma Endocrinology Inc | 21 | $13,003 |
| Rhythm Pharmaceuticals, Inc. | 7 | $7,969 |
| Endo Pharmaceuticals Inc. | 6 | $6,654 |
| Novo Nordisk | 2 | $2,072 |
| Eton Pharmaceuticals, Inc. | 1 | $1,500 |
| Pfizer | 1 | $1,200 |
| Biomarin Pharmaceutical Inc. | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRENESSITY$27,288
- SKYTROFA$9,909
- SUPPRELIN$6,654
- Norditropin$2,040
- Alkindi$1,500
- KHINDIVI$1,500
- INCRELEX$1,500
- GENOTROPIN$1,200
How this compares
$61,584 in reported general payments places this provider in the 90th percentile of 25 pediatric endocrinology providers in Minnesota.
Other pediatric endocrinology in Saint Paul
- Lauren YauchSaint Paul$544
- Sandy LiuSaint Paul$190
- Angela TridgellSaint Paul$104
- Tanya HalvorsenSaint Paul$32
- Bradley MillerMinneapolis$465K
- Antoinette MoranMinneapolis$63K
- Amy CriegoSt Louis Park$60K
- Melena BellinMinneapolis$56K
- Ana CreoRochester$44K
- Laura Gandrud PickettSt Louis Park$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.